Sort
51,593 grants matching “hepatitis”
NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in Humans
$906,964Ruy M Ribeiro · Triad National Security, Llc · R01 · FY2023 · AI
A point of care-device for the determination of creatinine phosphokinase (CPK), theCPK Now
$906,002Robert Harper · Analytical Diagnostic Solutions, Inc. · R44 · FY2025 · HD
JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT
$905,675Charles W. Flexner · Johns Hopkins University · U01 · FY2006 · AI
Genetic susceptibility and common multi-factorial retinal/macular diseases
$905,275Anand Swaroop · National Eye Institute · ZIA · FY2010 · EY
NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in Humans
$904,941Ruy M Ribeiro · Triad National Security, Llc · R01 · FY2024 · AI
CIP Genomics Core
$904,241Colm Ohuigin · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA
Clinical Research Network in Non-Alcoholic Steatohepati*
$904,151Johns Hopkins University · U01 · FY2002 · DK
Project 3 - Flavivirus - UTMB
$903,330Pei-Yong Shi · University Of Alabama At Birmingham · U19 · FY2019 · AI
CPCRA-PHILADELPHIA FIGHT
$903,051Philadelphia Fight · U01 · FY2002 · AI
Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Virus
$902,942Brian H. Johnston · Somagenics, Inc. · R44 · FY2018 · AI
TOPMed Omics of Type 2 Diabetes and Quantitative Traits
$902,027James B Meigs · Massachusetts General Hospital · UM1 · FY2021 · DK
Determinants of the racial/ethnic disparity in MGUS risk: An epidemiologic study in 4 cohorts
$901,929Wendy Cozen · University Of California-Irvine · R01 · FY2025 · CA
Western States Node of the National Drug Abuse Treatment Clinical Trials Network
$901,841James L. Sorensen · University Of California, San Francisco · UG1 · FY2017 · DA
Management of Pediatric Type 2 Diabetes Mellitus
$901,706Lorraine E Katz · Children'S Hosp Of Philadelphia · U01 · FY2008 · DK
HIV and musculoskeletal frailty: implications for care, policy and research
$901,598Elena Losina · Brigham And Women'S Hospital · R01 · FY2022 · NR
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
$901,490Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2015 · AI
Multicenter AIDS Cohort Study
$901,232Charles R Rinaldo · University Of Pittsburgh At Pittsburgh · U01 · FY2009 · AI
A single antiviral to treat multiple opportunistic infections
$901,086Stacy Remiszewski · Evrys Bio, Llc · R44 · FY2020 · AI
Project SHIELD: Police Education to Support Public Health in Kentucky
$900,881Javier Cepeda · Johns Hopkins University · R61 · FY2024 · DA
CCR, LGI, Flow Cytometry Core Facility
$900,397Karen Wolcott · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA
Knockdown of Gene Expression in Immune Cells in Humanized Mice
$900,285Judy Lieberman · Boston Children'S Hospital · RC4 · FY2010 · AI
Novel Small Molecules For Acute Liver Failure
$900,132Prakash Narayan · Angion Biomedica Corporation · R44 · FY2007 · AA
MOLECULAR PATHOGENESIS OF DIGESTIVE DISEASES
$900,000Stanford University · P30 · FY2004 · DK
MOLECULAR PATHOGENESIS OF DIGESTIVE DISEASES
$900,000Stanford University · P30 · FY2001 · DK
MOLECULAR PATHOGENESIS OF DIGESTIVE DISEASES
$900,000Stanford University · P30 · FY2003 · DK